Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2025 | Underweight → Equal-Weight | Morgan Stanley | |
| 1/13/2025 | $40.00 → $15.00 | Outperform → Market Perform | BMO Capital Markets |
| 11/21/2024 | $8.00 | Underweight | Morgan Stanley |
| 9/23/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 4/15/2024 | $45.00 | Overweight | Barclays |
| 4/15/2024 | $459.00 | Overweight | Barclays |
| 2/7/2024 | $81.00 | Buy | Goldman |
| 10/26/2023 | $25.00 | Outperform | RBC Capital Mkts |
Morgan Stanley upgraded 4D Molecular Therapeutics from Underweight to Equal-Weight
BMO Capital Markets downgraded 4D Molecular Therapeutics from Outperform to Market Perform and set a new price target of $15.00 from $40.00 previously
Morgan Stanley initiated coverage of 4D Molecular Therapeutics with a rating of Underweight and set a new price target of $8.00
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 8th Annual Evercore Healthcare Conference Presentation Date:Wednesday, Dec 3, 2025Presentation Time:2:35 p.m. ETWebcast Link:Webcast Archived copies of the webcast will be available for up to
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience
Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of distinguished retina industry advisors enhances global development and commercialization expertise EMERYVILLE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced senior leadership additi
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic mouse models and in non-human primates (NHP)CFH variants with reduced complement inhibitory function are a well-validated genetic risk factor for GA secondary to age-related macular degeneration (AMD), with approximately 75% of AMD patients carrying a high-risk variant of CFH; utilizing a precision medicine approach, this population represents a potential target population for 4D-175Continues expans
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)